Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of EX103 injection in relapsed or refractory CD20-positive non-Hodgkin lymphoma
CTR20212096Phase 2Active
- Sponsor
- ExcelMab
- Start
- Oct 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of EX103 in non-Hodgkin lymphoma (NHL), mature B-cell lymphoma, sponsored by ExcelMab. Started Oct 2021; status: active.
02
Drugs
EX103
03
Conditions
non-Hodgkin lymphoma (NHL)mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20212096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212096.